68,300 Shares of Guardant Health, Inc. $GH Acquired by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 68,300 shares of the company’s stock, valued at approximately $12,182,000. Nan Fung Trinity HK Ltd. owned approximately 0.05% of Guardant Health at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Maryland State Retirement & Pension System boosted its stake in shares of Guardant Health by 15.0% in the 3rd quarter. Maryland State Retirement & Pension System now owns 7,793 shares of the company’s stock valued at $1,390,000 after purchasing an additional 1,015 shares in the last quarter. Jacobi Capital Management LLC bought a new stake in Guardant Health in the third quarter worth $35,000. Machina Capital S.A.S. purchased a new stake in Guardant Health during the third quarter valued at about $3,098,000. Illinois Municipal Retirement Fund boosted its position in Guardant Health by 52.9% during the third quarter. Illinois Municipal Retirement Fund now owns 9,976 shares of the company’s stock valued at $1,779,000 after buying an additional 3,450 shares during the period. Finally, New York Life Investment Management LLC grew its stake in shares of Guardant Health by 12.3% during the third quarter. New York Life Investment Management LLC now owns 18,876 shares of the company’s stock valued at $3,367,000 after buying an additional 2,067 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on GH. UBS Group lifted their price objective on Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Roth Capital initiated coverage on Guardant Health in a research report on Thursday, October 22nd. They set a “buy” rating and a $200.00 price target on the stock. Piper Sandler decreased their price target on Guardant Health from $193.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research note on Tuesday, August 25th. Finally, BTIG Research boosted their price objective on Guardant Health from $195.00 to $210.00 and gave the company a “buy” rating in a research report on Tuesday, October 27th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $190.88.

Insiders Place Their Bets

In other news, Director Alex M. Azar II sold 826 shares of Guardant Health stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total value of $144,550.00. Following the sale, the director directly owned 825 shares in the company, valued at approximately $144,375. This trade represents a 50.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Steve E. Krognes sold 6,674 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total value of $1,172,888.76. Following the transaction, the director directly owned 7,906 shares in the company, valued at $1,389,400.44. This trade represents a 45.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 53,155 shares of company stock worth $9,107,025. 5.60% of the stock is currently owned by company insiders.

Guardant Health Trading Up 0.1%

GH stock opened at $154.86 on Friday. The firm’s 50-day moving average price is $168.83 and its two-hundred day moving average price is $132.81. Guardant Health, Inc. has a 12-month low of $74.55 and a 12-month high of $191.05. The stock has a market capitalization of $20.95 billion, a price-to-earnings ratio of -42.08 and a beta of 1.67.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The firm had revenue of $360.98 million for the quarter, compared to analysts’ expectations of $350.72 million. The business’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.74) earnings per share. Equities analysts predict that Guardant Health, Inc. will post -3.08 EPS for the current year.

Guardant Health Company Profile

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.